The Chinese biotech market is at a nascent stage, when compared to its counterpart in the US, Europe, and Japan. The country, however, has the potential to dominate the world biotech market. Its cheap labor costs, strong biodiversity, immense government support, and a huge pool of human resources are enabling the country to flourish in every segment of the biotech. The biotechnology capabilities of China can be envisaged from the fact that, the country not only represents a strong destination for exports, but also promises a huge domestic market. Consequently, the biotech market in China is forecasted to grow at a CAGR of around 23% during 2010 - 2012, says our new research report "Asia Pacific Biotechnology Market (2008-2012)".Our team of experts has found various reasons, which have been driving the biotech industry in the country. Among several factors discussed in the report, main factor is the use of nanotechnology in the biotech industry. The biotechnology companies in the country have been investing huge chunk of money on promoting the applications of nanotechnology. Along with this, several other factors, such as huge pool of human resource and large domestic market will also drive the growth of the market.Moreover, our report provides detail country profiles of various countries. The countries covered in our report are Japan, China, India, South Korea, Taiwan, Australia, New Zealand, Singapore, and Malaysia. Most importantly, for each country included in the report, we have provided detail description of key players and the regulatory framework.Our report "Asia Pacific Biotechnology Market (2008-2012)" provides thorough analysis of the various segments of the biotech industry, such as biopharma, bioservices, bioagriculture, industrial biotechnology, and bioinformatics together with the detail study of the investment opportunities in various countries discussed in our report. The report has thoroughly examined current market trends; industrial developments, and competitive landscape to enable clients understand the market structure and its progress in coming years. Due consideration has been given to the possible after effects of recession on the industry. It will help clients to have a proper insight of the current and future outlook of the biotech market in the Asia Pacific region.